MSTN and diabetes mellitus: With this study, we sought to evaluate whether pharmacologic inhibition of myostatin with a myostatin inhibitory antibody (REGN647) improves muscle and bone mass, as well as muscle and bone strength, in a mouse model of insulin‐deficient diabetes.